Table 2.

Demographic and tumor characteristics of statin users and nonusers in PCaP

Statin nonusers (n = 1,205)Statin users (n = 725)P
Age at diagnosis, mean (SD)62 (8)65 (7)<0.0001
Race
 CA604 (50)408 (56)0.009
 AA601 (50)317 (44)
Site
 North Carolina602 (50)325 (45)0.029
 Louisiana603 (50)400 (55)
Clinical stage
 T1679 (56)389 (54)0.249
 T2–T4526 (44)336 (46)
PSA, median (IQR)5.8 (4.3–9.8)5.3 (4.1–7.6)<0.0001
Biopsy Gleason sum
 ≤3 + 4941 (79)590 (82)0.101
 ≥4 + 3256 (21)132 (18)
Aggressive prostate cancer
 Low/intermediate972 (81)614 (85)0.025
 High233 (19)111 (15)
Prostate cancer screening frequency
 Never278 (23)82 (11)<0.0001
 ≤1 Test per year365 (30)260 (36)
 >1 Test per year562 (47)383 (53)
Family history of prostate cancer (first-degree relative)a
 No811 (73)503 (75)0.214
 Yes304 (27)164 (25)
Education
 Less than high school234 (19)125 (17)0.320
 High school graduate299 (25)171 (24)
 College graduate or some college672 (56)428 (59)
Incomeb
 <$20,000238 (22)126 (19)0.331
 $20,000–$50,000361 (33)234 (35)
 $50,000–$80,000221 (20)145 (22)
 >$80,000284 (25)158 (24)
Smoking status
 Never407 (34)243 (34)<0.0001
 Former585 (49)407 (56)
 Current213 (18)75 (10)
BMI (kg/m2)
 <30793 (66)400 (55)<0.0001
 ≥30412 (34)325 (45)
Charlson comorbidity index
 0697 (58)281 (39)<0.0001
 ≥1508 (42)444 (61)
Cardiovascular disease
 No1,104 (92)508 (71)<0.0001
 Yes95 (8)210 (29)
Diabetes
 No1,022 (85)494 (69)<0.0001
 Yes179 (15)226 (31)
Dietary cholesterol intake (mg/day)288 (198–406)269 (179–368)0.0001
Percent saturated fat intake, mean (SD)10.6 (2.7)10.7 (2.7)0.811
Nonstatin cholesterol-lowering drug use
 None1,123 (93)563 (78)<0.0001
 Niacin/fibrate/ezetimibe82 (7)162 (22)

Abbreviation: IQR, interquartile range.

  • aFamily history missing for 90 statin nonusers and 58 statin users.

  • bIncome was missing for 27 statin nonusers and 16 statin users, whereas 74 statin nonusers and 46 statin users refused to answer this question.